2. Academic Validation
  3. Phenformin as an Anticancer Agent: Challenges and Prospects

Phenformin as an Anticancer Agent: Challenges and Prospects

  • Int J Mol Sci. 2019 Jul 5;20(13):3316. doi: 10.3390/ijms20133316.
Mª Eugenia García Rubiño 1,  Esmeralda Carrillo 2 3 4 5 6,  Gloria Ruiz Alcalá 2 4,  Alicia Domínguez-Martín 5,  Juan A Marchal 2 3 4 5 6,  Houria Boulaiz 7 8 9 10 11
Affiliations

Affiliations

  • 1 Department of Physical Chemistry, Faculty of Pharmacy, University of Granada, 18071 Granada, Spain.
  • 2 Biopathology and Regenerative Medicine Institute (IBIMER), Centre for Biomedical Research, University of Granada, E-18100 Granada, Spain.
  • 3 Department of Human Anatomy and Embryology, Faculty of Medicine, University of Granada, E-18012 Granada, Spain.
  • 4 Instituto de Investigación Biosanitaria de Granada (ibs. GRANADA), University Hospitals of Granada-University of Granada, 18012 Granada, Spain.
  • 5 Fundamental Biology Service, Scientific Instrument Center, University of Granada, 18071 Granada, Spain.
  • 6 Research Unit "Modeling Nature" (MNat), University of Granada, 18016 Granada, Spain.
  • 7 Biopathology and Regenerative Medicine Institute (IBIMER), Centre for Biomedical Research, University of Granada, E-18100 Granada, Spain. [email protected].
  • 8 Department of Human Anatomy and Embryology, Faculty of Medicine, University of Granada, E-18012 Granada, Spain. [email protected].
  • 9 Instituto de Investigación Biosanitaria de Granada (ibs. GRANADA), University Hospitals of Granada-University of Granada, 18012 Granada, Spain. [email protected].
  • 10 Fundamental Biology Service, Scientific Instrument Center, University of Granada, 18071 Granada, Spain. [email protected].
  • 11 Research Unit "Modeling Nature" (MNat), University of Granada, 18016 Granada, Spain. [email protected].
PMID: 31284513 DOI: 10.3390/ijms20133316
Abstract

Currently, there is increasing evidence linking diabetes mellitus (especially type 2 diabetes mellitus) with carcinogenesis through various biological processes, such as fat-induced chronic inflammation, hyperglycemia, hyperinsulinemia, and angiogenesis. Chemotherapeutic agents are used in the treatment of Cancer, but in most cases, patients develop resistance. Phenformin, an oral biguanide drug used to treat type 2 diabetes mellitus, was removed from the market due to a high risk of fatal lactic acidosis. However, it has been shown that phenformin is, with other biguanides, an authentic tumor disruptor, not only by the production of hypoglycemia due to caloric restriction through AMP-activated protein kinase with energy detection (AMPK) but also as a blocker of the mTOR regulatory complex. Moreover, the addition of phenformin eliminates resistance to antiangiogenic tyrosine kinase inhibitors (TKI), which prevent the uncontrolled metabolism of glucose in tumor cells. In this review, we evidence the great potential of phenformin as an Anticancer agent. We thoroughly review its mechanism of action and clinical trial assays, specially focusing on current challenges and future perspectives of this promising drug.

Keywords

biguanides; cancer; cancer stem cells; diabetes type 2; phenformin.

Figures
Products